Interacting Drugs |
Ketorolac (systemic) vs Neuromuscular-Blocking Agents (Nondepolarizing) |
Security Level |
|
Mechanism |
Neuromuscular-Blocking Agents (Nondepolarizing): Ketorolac (Systemic) may enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination. |
Management |
Monitor therapy |
Ketorolac (systemic) vs Neuromuscular-Blocking Agents (Nondepolarizing)
Post Review about Ketorolac (systemic) vs Neuromuscular-Blocking Agents (Nondepolarizing) Click here to cancel reply.
Other Interactions of Ketorolac (systemic)
Other Interactions of Neuromuscular-Blocking Agents (Nondepolarizing)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.